214 related articles for article (PubMed ID: 23509154)
1. Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors.
Altman JK; Szilard A; Konicek BW; Iversen PW; Kroczynska B; Glaser H; Sassano A; Vakana E; Graff JR; Platanias LC
Blood; 2013 May; 121(18):3675-81. PubMed ID: 23509154
[TBL] [Abstract][Full Text] [Related]
2. Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.
Kosciuczuk EM; Saleiro D; Kroczynska B; Beauchamp EM; Eckerdt F; Blyth GT; Abedin SM; Giles FJ; Altman JK; Platanias LC
Blood; 2016 Jul; 128(3):410-4. PubMed ID: 27307295
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
4. Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses.
Altman JK; Glaser H; Sassano A; Joshi S; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Tallman MS; Platanias LC
Mol Pharmacol; 2010 Oct; 78(4):778-84. PubMed ID: 20664001
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.
Chen S; Cui L; Hu Q; Shen Y; Jiang Y; Zhao J
Biochem Biophys Res Commun; 2020 Sep; 530(1):142-148. PubMed ID: 32828276
[TBL] [Abstract][Full Text] [Related]
6. Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer.
Zhu Y; Wang C; Li M; Yang X
J Pharm Pharmacol; 2021 Sep; 73(10):1418-1426. PubMed ID: 34254647
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S
Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells.
Bianchini A; Loiarro M; Bielli P; Busà R; Paronetto MP; Loreni F; Geremia R; Sette C
Carcinogenesis; 2008 Dec; 29(12):2279-88. PubMed ID: 18809972
[TBL] [Abstract][Full Text] [Related]
9. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
[TBL] [Abstract][Full Text] [Related]
10. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting MNK Selectively Targets Cervical Cancer via Suppressing eIF4E-Mediated β-Catenin Activation.
Zhang W; Su X; Li S; Wang Y; Wang Q; Zeng H
Am J Med Sci; 2019 Sep; 358(3):227-234. PubMed ID: 31327462
[TBL] [Abstract][Full Text] [Related]
13. Unveiling new chemical scaffolds as Mnk inhibitors.
Diab S; Li P; Basnet SK; Lu J; Yu M; Albrecht H; Milne RW; Wang S
Future Med Chem; 2016; 8(3):271-85. PubMed ID: 26910782
[TBL] [Abstract][Full Text] [Related]
14. The MNK-eIF4E Signaling Axis Contributes to Injury-Induced Nociceptive Plasticity and the Development of Chronic Pain.
Moy JK; Khoutorsky A; Asiedu MN; Black BJ; Kuhn JL; Barragán-Iglesias P; Megat S; Burton MD; Burgos-Vega CC; Melemedjian OK; Boitano S; Vagner J; Gkogkas CG; Pancrazio JJ; Mogil JS; Dussor G; Sonenberg N; Price TJ
J Neurosci; 2017 Aug; 37(31):7481-7499. PubMed ID: 28674170
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of SEL201 in acute myeloid leukemia.
Kosciuczuk EM; Kar AK; Blyth GT; Fischietti M; Abedin S; Mina AA; Siliezar R; Rzymski T; Brzozka K; Eklund EA; Beauchamp EM; Eckerdt F; Saleiro D; Platanias LC
Oncotarget; 2019 Dec; 10(67):7112-7121. PubMed ID: 31903169
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.
Kosciuczuk EM; Saleiro D; Platanias LC
Cytokine; 2017 Jan; 89():116-121. PubMed ID: 27094611
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.
Wu H; Hu C; Wang A; Weisberg EL; Chen Y; Yun CH; Wang W; Liu Y; Liu X; Tian B; Wang J; Zhao Z; Liang Y; Li B; Wang L; Wang B; Chen C; Buhrlage SJ; Qi Z; Zou F; Nonami A; Li Y; Fernandes SM; Adamia S; Stone RM; Galinsky IA; Wang X; Yang G; Griffin JD; Brown JR; Eck MJ; Liu J; Gray NS; Liu Q
Leukemia; 2016 Jan; 30(1):173-81. PubMed ID: 26165234
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening.
Mishra RK; Clutter MR; Blyth GT; Kosciuczuk EM; Blackburn AZ; Beauchamp EM; Schiltz GE; Platanias LC
Chem Biol Drug Des; 2019 Oct; 94(4):1813-1823. PubMed ID: 31260185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
